

# Bias in Artificial Intelligence: Legal Risks and Solutions

Virtual Briefing (ET)  
March 23, 2021 | Events

You've likely seen the headlines. Online recruiting tools that unfairly screen out women and minorities. Facial recognition tools used in law enforcement that misidentify specific demographic groups. Algorithms that place white patients ahead of patients of color in line for health care. While the potential human costs of biased AI are of paramount importance, what are the legal implications of misguided, flawed, or discriminatory algorithms for your business? This virtual briefing will sort through where algorithmic bias crosses the line into the illegal, and what companies can do about it.

Join us on **Tuesday, March 23, 2021** as we explore the legal risks of and solutions to bias in AI. Our outstanding panel of presenters will provide tangible solutions to addressing bias in the form of technical solutions as well as improvements to the governance process for the development and use of AI.

The breakout sessions will work through case studies specific to issues in health care and life sciences, labor and employment, and liability.

Presenters will include Keith E. Sonderling, Commissioner of the **U.S. Equal Employment Opportunity Commission (EEOC)**; Dr. Francesca Rossi, IBM Fellow and AI Ethics Global Leader from **IBM**; and Derek Snidauf, Principal, Don Williams, Senior Manager, and Daniel Yoo, Manager from **Deloitte Transactions and Business Analytics LLP**.

## People



Lynn Shapiro Snyder  
Strategic Advisor  
Artificial Intelligence  
202-861-1806  
lsnyder@ebglaw.com



Bradley Merrill Thompson  
Strategic Advisor  
Artificial Intelligence  
202-861-1817  
bthompson@ebglaw.com

## Focus Areas

### Services

Artificial Intelligence

[Click here for the full agenda.](#)

**Who Should Attend:**

General Counsel and other law department leaders, leaders in human resources including Chief Talent/Acquisition Officer, and other organizational leaders such as Chief Information Officers, Chief Compliance Officers and Chief Regulatory Officers (FDA).

***Update: For questions about the briefing materials, please contact [Matt Loomis](#) or [Dionna Rinaldi](#).***

*Members of the media, please contact [Piper L. Hall](#).*